Integrating the result from the CVOTs in their meta-analysis, Sattar and colleagues found that the GLP-1 RA drug class may reduce the risk of hospital admission for HF by 11% (HR vs. placebo of 0.89, 95%CI 0.82–0.98) (Sattar et al., 2021). The gene discussed is GLP1R; the disease is hydrops fetalis.